ImmunityBio Secures $100 Million in Funding to Revolutionize Immune System-based Therapies

ImmunityBio, Inc., a pioneering force in the field of cell and immunotherapy, has successfully raised $100 million in its latest funding round. Founded in 2014 by the visionary Dr. Patrick Soon-Shiong, the company is dedicated to transforming the treatment landscape for oncology and infectious diseases by leveraging the innate power of the human immune system. ImmunityBio aims to develop revolutionary therapies that not only combat current health challenges but also build long-lasting immunological memory to improve patient outcomes over time. This significant funding will be pivotal in accelerating the development of their innovative cell and immunotherapy products, which are designed to empower patients' natural defenses and tackle cancerous or infected cells in a groundbreaking way. As Dr. Soon-Shiong articulately stated, "At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it." The capital raised will support ongoing research projects and clinical trials, advancing the company's mission to unlock the full potential of immunotherapy. By reinforcing both branches of the immune response, ImmunityBio is set on a path to reprogram patients' immune systems, therapies that treat the person rather than just the disease itself. As we stand on the brink of a new era in cancer treatment, this funding signifies a critical step towards realizing ImmunityBio’s vision of a world where cancer is an ordeal of the past.